| Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers P Palatini, L Tedeschi, G Frison, R Padrini, R Zordan, R Orlando, ... European journal of clinical pharmacology 45, 353-356, 1993 | 319 | 1993 |
| Pharmacokinetics of gamma‐hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. SD Ferrara, S Zotti, L Tedeschi, G Frison, F Castagna, L Gallimberti, ... British journal of clinical pharmacology 34 (3), 231-235, 1992 | 236 | 1992 |
| Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis R Orlando, M Mussap, M Plebani, P Piccoli, S De Martin, M Floreani, ... Clinical chemistry 48 (6), 850-858, 2002 | 209 | 2002 |
| A comparison between different methods for the determination of reduced and oxidized glutathione in mammalian tissues M Floreani, M Petrone, P Debetto, P Palatini Free Radical Research 26 (5), 449-455, 1997 | 147 | 1997 |
| Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography—mass spectrometry SD Ferrara, L Tedeschi, G Frison, F Castagna, L Gallimberti, R Giorgetti, ... Journal of pharmaceutical and biomedical analysis 11 (6), 483-487, 1993 | 138 | 1993 |
| Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function R Orlando, P Piccoli, S De Martin, R Padrini, M Floreani, P Palatini Clinical Pharmacology & Therapeutics 75 (1), 80-88, 2004 | 130 | 2004 |
| Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes L Quintieri, P Palatini, A Nassi, P Ruzza, M Floreani Biochemical pharmacology 75 (6), 1426-1437, 2008 | 109 | 2008 |
| Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity M Floreani, E Napoli, L Quintieri, P Palatini Life sciences 72 (24), 2741-2750, 2003 | 107 | 2003 |
| Pharmacokinetics of intraperitoneal cisplatin and doxorubicin CR Rossi, S Mocellin, P Pilati, M Foletto, L Quintieri, P Palatini, M Lise Surgical Oncology Clinics 12 (3), 781-794, 2003 | 100 | 2003 |
| Reduction of erythrocyte (Na+-K+)ATPase activity in Type 1 (insulin-dependent) diabetic subjects and its activation by homologous plasma P Finotti, P Palatini Diabetologia 29, 623-628, 1986 | 99 | 1986 |
| Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. P Finotti, P Palatini Journal of Pharmacology and Experimental Therapeutics 217 (3), 784-790, 1981 | 95 | 1981 |
| Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and … CR Rossi, M Foletto, S Mocellin, P Pilati, M De Simone, M Deraco, ... Cancer 94 (2), 492-499, 2002 | 93 | 2002 |
| Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis S De Martin, R Orlando, M Bertoli, P Pegoraro, P Palatini Clinical Pharmacology & Therapeutics 80 (6), 597-606, 2006 | 92 | 2006 |
| Pharmacokinetic drug interactions in liver disease: an update P Palatini, S De Martin World Journal of Gastroenterology 22 (3), 1260, 2016 | 87 | 2016 |
| Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. R Orlando, M Floreani, R Padrini, P Palatini Clinical nephrology 51 (6), 341-347, 1999 | 85 | 1999 |
| Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function R Orlando, P Piccoli, S De Martin, R Padrini, P Palatini British journal of clinical pharmacology 55 (1), 86-93, 2003 | 72 | 2003 |
| Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers SD Ferrara, R Giorgetti, S Zancaner, R Orlando, A Tagliabracci, ... European Journal of Clinical Pharmacology 54, 821-827, 1999 | 69 | 1999 |
| Cardiovascular risk factors in the elderly. E Casiglia, P Palatini Journal of human hypertension 12 (9), 1998 | 66 | 1998 |
| Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid SD Ferrara, L Tedeschi, G Frison, R Orlando, M Mazzo, R Zordan, ... European journal of clinical pharmacology 50, 305-310, 1996 | 66 | 1996 |
| Activation of (Na++ K+)-dependent ATPase by lipid vesicles of negative phospholipids. P Palatini, F Dabbeni-Sala, A Pitotti, A Bruni, JC Mandersloot Biochimica et Biophysica Acta 466 (1), 1-9, 1977 | 66 | 1977 |
